-
Mashup Score: 5Novel Selective Biomarker May Help Select Effective Targeted Therapies in Patients With Metastatic Breast Cancer - The ASCO Post - 5 month(s) ago
A novel selective biomarker (Troplex) may help select which antibody-drug conjugate therapy could be most effective in patients with metastatic breast cancer, according to findings presented by Robbins et al at the 2023 San Antonio Breast Cancer Symposium (Abstract PO3-13-11). Antibody-drug conjugates are a type of targeted therapy designed to release cancer drugs to specific tumor cells. However, their efficacy often depends on target expression and the best method for measuring expression is still
Source: www.ascopost.comCategories: General Medicine News, Onc News and JournalsTweet
-
Mashup Score: 10Novel Targeted Therapies May Benefit Patients With Metastatic HR-Positive/HER2-Negative Breast Cancer - The ASCO Post - 5 month(s) ago
Two studies led by researchers at The University of Texas MD Anderson Cancer Center demonstrated clinical benefit from novel targeted therapies, which may offer new treatment options for patients with metastatic hormone receptor–positive/HER2-negative breast cancer. The data were shared in oral presentations at the 2023 San Antonio Breast Cancer Symposium. According to the National Cancer Institute, hormone receptor–positive/HER2-negative breast cancer is the predominant breast cancer subtype in the
Source: www.ascopost.comCategories: General Medicine News, Onc News and JournalsTweet-
Novel Targeted Therapies May Benefit Patients With Metastatic Hormone Receptor–Positive/HER2-Negative Breast Cancer https://t.co/TuVpT7SxAd #bcsm #breastcancer #oncology #SABCS23 @SABCSSanAntonio
-
-
Mashup Score: 1Umbraco - www.ascopost.com - 6 month(s) ago
Password Show password Hide password
Source: www.ascopost.comCategories: General Medicine News, Onc News and JournalsTweet-
.@US_FDA Approves First Treatment for Patients With cTTP https://t.co/wrCOkKt0aD #hematology
-
-
Mashup Score: 3Intraductal Papillary Mucinous Neoplasms: Risk of Pancreatic Cancer - The ASCO Post - 6 month(s) ago
In a retrospective cohort study reported in JAMA Network Open, de la Fuente et al found that the risk of pancreatic cancer in patients with Fukuoka criteria–negative intraductal papillary mucinous neoplasms (F-N IPMNs) did not differ from that in patients without IPMNs. In addition, the small proportion of patients with pancreatic cancer associated with IPMNs (IPMN-PC) had better survival vs patients with non–IPMN PC. The study was conducted in Olmsted County, Minnesota, using the Rochester Epidemiology
Source: www.ascopost.comCategories: General Medicine News, Onc News and JournalsTweet-
Intraductal Papillary Mucinous Neoplasms: Risk of Pancreatic Cancer https://t.co/hK4HS4xvWh #pancsm #pancreaticcancer #oncology
-
-
Mashup Score: 0Mount Sinai Health System - 9 month(s) ago
Join/Renew Cancer Program Membership …
Source: www.ascopost.comCategories: Hem/Oncs, Latest HeadlinesTweet-
2023 Assoc of Commnty Cancer Ctrs INNOVATOR AWARD @ACCCBuzz The first advanced practice radiation therapist role in the US at the Mt Sinai Health System “Working in tandem w/ #radonc… by task-shifting” Will be presented at the Oct 2023 Conference https://t.co/nOgyhiyAZx
-
-
Mashup Score: 1Nurses’ Role in Oral Oncolytics for CLL – [VIDEO PODCAST] Ep 28 - 1 year(s) ago
Learn about a nurse’s role in care planning, and engaging patients in education, and shared decision making for treatment goals and planning.
Source: www.ascopost.comCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
RT @ACCCBuzz: 🚨 *NEW* CANCER BUZZ episode: https://t.co/iJe48E3ibB @hopkinskimmel @HopkinsMedicine Treatment for patients with #CLL has und…
-
-
Mashup Score: 0
By The ASCO Post Staff Posted: 1/4/2023 10:34:00 AM Last Updated: 1/4/2023 11:05:30 AM Research conducted by UC Davis Comprehensive Cancer Center and the University of Cincinnati showed that direct oral anticoagulants (DOACs) are more effective—and more cost-effective—than low–molecular-weight heparin for…
Source: www.ascopost.comCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
Study Compares the Cost and Efficacy of Anticoagulant Therapies https://t.co/xScbKc3sM6 #anticoagulants #cancer #oncology
-
-
Mashup Score: 0
Navigating difficult conversations with patients facing advanced-stage cancer is an important part of shared decision making and ensuring patients feel engaged with their treatment plan.
Source: www.ascopost.comCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
Hear from Sunandana Chandra, MD, (@MunTheLoon) from @LurieCancer @NorthwesternMed about her approach to having difficult conversations with patients facing advanced #cancer. Listen to the @ACCCBuzz podcast: https://t.co/1qzq6bA1nd #palliativecare #SuppOnc #PallOnc https://t.co/nGnw5XbKd0
-
-
Mashup Score: 2Patient Adherence to Oral Targeted Therapies — [VODCAST] Ep 18 - 2 year(s) ago
With the emergence of oral cancer therapies, it is a very exciting time in cancer care. But these treatments can come with adverse events.
Source: www.ascopost.comCategories: Hem/Oncs, Latest HeadlinesTweet-
RT @ACCCBuzz: @maryam_lustberg @yalecancer @yalemed & Sandra Cuellar @UICPharm join the CANCER BUZZ vodcast: https://t.co/oJqEvdF0Ai Tune i…
-
-
Mashup Score: 0Clinical Research Award - 2 year(s) ago
The Clinical Research Award recognizes individuals whose research has significantly and positively impacted the oncology patient, family, and/or community. 2022 Clinical Research Award Recipient: Carmen Guerra, MD, MSCE, FACP Dr. Carmen Guerra is the Ruth C. and Raymond G. Perelman Professor of Medicine at the Perelman School of Medicine at the University of Pennsylvania. Dr. Guerra is a…
Source: www.ascopost.comCategories: Hem/Oncs, Latest HeadlinesTweet-
Congratulations, Dr. Carmen Guerra!! Well-deserved! Clinical Research Award https://t.co/0Q70TW05Lw @PennCancer @UofPenn
-
Novel Selective Biomarker May Help Select Effective Targeted Therapies in Patients With Metastatic Breast Cancer https://t.co/iaYDjhJWN8 #SABCS23 @SABCSSanAntonio #bcsm #breastcancer #oncology #biomarker